These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 23269608)

  • 1. An association between XPC Lys939Gln polymorphism and the risk of bladder cancer: a meta-analysis.
    Zhang Y; Wang X; Zhang W; Gong S
    Tumour Biol; 2013 Apr; 34(2):973-82. PubMed ID: 23269608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The association between XPC Lys939Gln gene polymorphism and urinary bladder cancer susceptibility: a systematic review and meta-analysis.
    Dou K; Xu Q; Han X
    Diagn Pathol; 2013 Jul; 8():112. PubMed ID: 23819639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. XPC gene polymorphisms contribute to bladder cancer susceptibility: a meta-analysis.
    Dai QS; Hua RX; Zeng RF; Long JT; Peng ZW
    Tumour Biol; 2014 Jan; 35(1):447-53. PubMed ID: 23918308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative assessment of the association between XPC Lys939Gln polymorphism and cutaneous melanoma risk.
    Zhou L; Lu Y; Yang G; Wu J
    Tumour Biol; 2014 Feb; 35(2):1427-32. PubMed ID: 24277375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. XPC Lys939Gln polymorphism contributes to colorectal cancer susceptibility: evidence from a meta-analysis.
    Peng Q; Lao X; Tang W; Chen Z; Li R; Qin X; Li S
    Diagn Pathol; 2014 Jun; 9():120. PubMed ID: 24947936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of XPC Polymorphisms with Cutaneous Malignant Melanoma Risk: Evidence from a Meta-Analysis.
    Asadian F; Niktabar SM; Ghelmani Y; Kargar S; Akbarian E; Emarati SA; Sadeghizadeh-Yazdi J; Neamatzadeh H
    Acta Medica (Hradec Kralove); 2020; 63(3):101-112. PubMed ID: 33002396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between CCND1 and XPC polymorphisms and bladder cancer risk: a meta-analysis based on 15 case-control studies.
    Wang Y; Li Z; Liu N; Zhang G
    Tumour Biol; 2014 Apr; 35(4):3155-65. PubMed ID: 24264314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymorphisms in the XPC gene affect urinary bladder cancer risk: a case-control study, meta-analyses and trial sequential analyses.
    Sankhwar M; Sankhwar SN; Bansal SK; Gupta G; Rajender S
    Sci Rep; 2016 Jun; 6():27018. PubMed ID: 27246180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations between polymorphisms of the XPC gene and lung cancer susceptibility: a meta-analysis.
    Zhu ML; Hua RX; Zheng L
    Tumour Biol; 2014 Apr; 35(4):2931-9. PubMed ID: 24375193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poly (AT) deletion/insertion polymorphism of the XPC gene contributes to urinary system cancer susceptibility: a meta-analysis.
    Dai QS; Hua RX; Zhang R; Huang YS; Hua ZM; Yun CT; Zeng RF; Long JT
    Gene; 2013 Oct; 528(2):335-42. PubMed ID: 23892089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The polyAT, intronic IVS11-6 and Lys939Gln XPC polymorphisms are not associated with transitional cell carcinoma of the bladder.
    Sak SC; Barrett JH; Paul AB; Bishop DT; Kiltie AE
    Br J Cancer; 2005 Jun; 92(12):2262-5. PubMed ID: 15886698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. XPC gene variants: a risk factor for recurrence of urothelial bladder carcinoma in patients on BCG immunotherapy.
    Gangwar R; Mandhani A; Mittal RD
    J Cancer Res Clin Oncol; 2010 May; 136(5):779-86. PubMed ID: 19924443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. XPC Lys939Gln and Ala499Val polymorphisms in colorectal cancer susceptibility: a meta-analysis of case-control studies.
    Liu C; Yin Q; Ying M; Lin J; Li L; Jiao G; Wang M; Wang Y
    Mol Biol Rep; 2014 Feb; 41(2):1171-8. PubMed ID: 24385304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of XPC polymorphisms and lung cancer risk: a meta-analysis.
    Jin B; Dong Y; Zhang X; Wang H; Han B
    PLoS One; 2014; 9(4):e93937. PubMed ID: 24736739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Associations of Lys939Gln and Ala499Val polymorphisms of the XPC gene with cancer susceptibility: a meta-analysis.
    He J; Shi TY; Zhu ML; Wang MY; Li QX; Wei QY
    Int J Cancer; 2013 Oct; 133(8):1765-75. PubMed ID: 23400628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of association between XPC Lys939Gln polymorphism and prostate cancer risk: an updated meta-analysis based on 3039 cases and 3253 controls.
    Wu H; Lv Z; Wang X; Zhang L; Mo N
    Int J Clin Exp Med; 2015; 8(10):17959-67. PubMed ID: 26770390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genotypes, haplotypes and diplotypes of XPC and risk of bladder cancer.
    Zhu Y; Lai M; Yang H; Lin J; Huang M; Grossman HB; Dinney CP; Wu X
    Carcinogenesis; 2007 Mar; 28(3):698-703. PubMed ID: 17052994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current evidences on XPC polymorphisms and gastric cancer susceptibility: a meta-analysis.
    Peng Q; Chen Z; Lu Y; Lao X; Mo C; Li R; Qin X; Li S
    Diagn Pathol; 2014 May; 9():96. PubMed ID: 24886180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymorphisms of the XPC gene may contribute to the risk of head and neck cancer: a meta-analysis.
    Zhang Y; Li Z; Zhong Q; Zhou W; Chen X; Chen X; Fang J; Huang Z
    Tumour Biol; 2014 Apr; 35(4):3917-31. PubMed ID: 24338715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A meta-analysis of evidences on XPC polymorphisms and lung cancer susceptibility.
    Liu C; Yin Q; Hu J; Li L; Zhang Y; Wang Y
    Tumour Biol; 2013 Apr; 34(2):1205-13. PubMed ID: 23381646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.